Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that ...
Pharmaceutical Technology on MSN7d
Taiho outlays $1.14bn to acquire ADC specialist ArarisTaiho Pharmaceutical has agreed to acquire Swiss-based antibody-drug-conjugate (ADC) specialist Araris Biotech for up to ...
TAIPEI, Taiwan, March 12, 2025 (GLOBE NEWSWIRE) -- At the ADC Asia Congress 2025 held today (3/12) in Singapore, OBI Pharma ...
Taiho Pharmaceutical Co., Ltd.Araris Biotech AGTaiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris ...
AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...
Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the ...
The Japanese pharmaceutical company Taiho Pharmaceutical is set to acquire the Swiss antibody-drug conjugate (ADC) company Araris Biotech for $400 million. Taiho and Araris have been collaborating to ...
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...
By acquiring Araris' innovative ADC drug discovery technology platform along with Cysteinomix, Taiho Pharmaceutical will further expand its ongoing development portfolio in the field of oncology.
Whitehawk Therapeutics (Nasdaq: WHWK), formerly Aadi Bioscience, has officially rebranded to reflect its transformation into ...
The pharma will acquire Araris Biotech to gain access to three preclinical ADCs and a linking technology Araris claims is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback